- Category
- Micro (2023-24)
- Udyam number
- UDYAM-UP-18-0003963

Reeford Pharmaceutical Private Limited
About Reeford Pharmaceutical Private Limited
Data last updated:
Reeford Pharmaceutical Private Limited is a private limited company based in Bulandshahr, Uttar Pradesh, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 17 June 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U52601UP2016PTC084109. Its GSTIN is 09AAHCR7943M1ZL (Uttar Pradesh).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Vimlesh Devi and Ravendra Kumar.
Its last annual general meeting (AGM) was held on 30 September 2019, and its latest financial statements are for the year ended 31 March 2019. The registered office is at Near Mandir Chandpur, Bulandshahr, Uttar Pradesh, India – 203001.
As per the financials filed for FY 2019, the company reported a revenue of ₹13.73 Lakh, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹2,090 (net margin 0.2%) and EBITDA of ₹2,090 (EBITDA margin 0.2%).
Reeford Pharmaceutical Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-18-0003963). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of Reeford Pharmaceutical
Contact details
Reeford Pharmaceutical Private Limited's registered office is in Bulandshahr, Uttar Pradesh. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressNear Mandir Chandpur, Bulandshahr, Uttar Pradesh, India – 203001
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Reeford Pharmaceutical Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Reeford Pharmaceutical is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Reeford Pharmaceutical Private Limited, buy the company report.
Financials of Reeford Pharmaceutical Private Limited
FY 2019 filings availableReeford Pharmaceutical Private Limited reported revenue of ₹13.73 Lakh (up 162% YoY) for FY 2019.
Compounded Annual Growth Rate (CAGR)
Revenue rose 162% in the latest year. EBITDA rose 542% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹2,090 | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹2,090 | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 0.2% | ||
| Net Profit Margin | 0.2% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Reeford Pharmaceutical Private Limited, buy the company report.
Board of directors of Reeford Pharmaceutical Private Limited
Reeford Pharmaceutical has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vimlesh Devi | Director | 17 Jun 2016 | 10 Years 4 Months | Current |
| Ravendra Kumar | Director | 17 Jun 2016 | 10 Years 4 Months | Current |
Auditor
Reeford Pharmaceutical Private Limited is audited by GAURAV GOEL & ASSOCIATES for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| GAURAV GOEL & ASSOCIATES | FY 2017 | 416025 |
Shareholding
The shareholding of Reeford Pharmaceutical Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Reeford Pharmaceutical Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Reeford Pharmaceutical Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Reeford Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Reeford Pharmaceutical has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAHCR7943M1ZL | Uttar Pradesh | Active | 02 May 2018 |
To see the full GST registrations and return filing status of Reeford Pharmaceutical Private Limited, buy the company report.
Recent activity
Reeford Pharmaceutical Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Ravendra Kumar was appointed as Director on 17 Jun 2016.
Frequently asked questions
Reeford Pharmaceutical is an active private limited company based in Bulandshahr, Uttar Pradesh, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 17 June 2016 (10+ years old) and is registered under CIN U52601UP2016PTC084109.
Reeford Pharmaceutical has 2 current directors:
- Vimlesh Devi - Director
- Ravendra Kumar - Director
The latest financial statements of Reeford Pharmaceutical on record with the MCA are for the year ended 31 March 2019. Its last annual general meeting was held on 30 September 2019. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Reeford Pharmaceutical is 09AAHCR7943M1ZL, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Reeford Pharmaceutical is U52601UP2016PTC084109. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Reeford Pharmaceutical was incorporated on 17 June 2016, making it 10+ years old. It is registered with the Registrar of Companies, Kanpur.
Ravendra Kumar was appointed as Director on 17 Jun 2016. Vimlesh Devi was appointed as Director on 17 Jun 2016.
Yes, Reeford Pharmaceutical is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-18-0003963).
The registered office of Reeford Pharmaceutical is at Near Mandir Chandpur, Bulandshahr, Uttar Pradesh, India – 203001.
Reeford Pharmaceutical operates in the pharma industry, in the pharmaceutical retailers and distributors segment.